The U.K. National Institute for Health and Care Excellence published draft guidance endorsing the use of Roche's MabThera as a treatment for some adults with anti-neutrophil cytoplasmic antibody-associated vasculitis. The treatment is a cost-effective use of the National Health Service's resources if further cyclophosphamide treatment would go beyond the maximum cumulative dose, NICE concluded.

Full Story:
PharmaTimes (U.K.)

Related Summaries